Privia Health Group (NASDAQ:PRVA) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Privia Health Group (NASDAQ:PRVA) from a strong sell rating to a hold rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

PRVA has been the subject of a number of other reports. Canaccord Genuity Group decreased their price objective on Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Barclays dropped their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Citigroup restated a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Finally, Evercore set a $26.00 price target on Privia Health Group in a report on Wednesday, April 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Privia Health Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.15.

Privia Health Group Stock Down 8.2%

NASDAQ PRVA opened at $22.00 on Wednesday. Privia Health Group has a 52-week low of $19.08 and a 52-week high of $28.82. The business’s 50-day moving average price is $24.61 and its 200 day moving average price is $23.35. The firm has a market cap of $2.77 billion, a P/E ratio of 137.51, a P/E/G ratio of 1.90 and a beta of 0.85.

Insiders Place Their Bets

In other news, CFO David Mountcastle sold 24,734 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $27.50, for a total value of $680,185.00. Following the completion of the sale, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at $5,135,020. This trade represents a 11.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the sale, the director owned 76,651 shares in the company, valued at approximately $1,941,569.83. This trade represents a 53.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 452,357 shares of company stock worth $11,436,655. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Durable Capital Partners LP boosted its position in shares of Privia Health Group by 1.8% during the 3rd quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after purchasing an additional 203,842 shares in the last quarter. State Street Corp increased its holdings in shares of Privia Health Group by 1.5% in the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock valued at $95,935,000 after purchasing an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. lifted its stake in shares of Privia Health Group by 5.4% in the first quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock valued at $83,371,000 after purchasing an additional 208,787 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Privia Health Group in the second quarter valued at about $74,425,000. Finally, Geode Capital Management LLC boosted its holdings in Privia Health Group by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock worth $66,738,000 after buying an additional 31,204 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Raised 2026 outlook: Management increased full-year guidance for attributed lives to 1.625–1.650 million, practice collections to the high end of $3.65–$3.75 billion, GAAP revenue to the high end of $2.35–$2.45 billion, and adjusted EBITDA to $145–$155 million. It also expects approximately 70%–80% of adjusted EBITDA to convert to free cash flow. Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
• Positive Sentiment: Strong quarterly growth: Q2 revenue rose 21.4% year over year to $632.6 million, exceeding the $597.3 million consensus. Adjusted EPS was $0.19 versus the $0.07 analyst estimate, while net income increased to $9.0 million from $2.7 million. Privia Health Q2 Earnings Report
• Positive Sentiment: Operating momentum improved: Implemented providers grew 10.1% to 5,644, value-based-care attributed lives increased 19.2% to 1.647 million, and adjusted EBITDA climbed 29.1% to $37.4 million. Adjusted EBITDA margin expanded to 28.3% from 25.2%.
• Neutral Sentiment: Analyst comparisons are complicated by differing definitions: GAAP diluted EPS was $0.07, while adjusted EPS was $0.19. The adjusted figure benefited from add-backs, including $19.4 million of non-cash stock compensation expense.
• Negative Sentiment: Cash-flow concerns: Privia used $48.4 million in operating cash during the first half, largely because accounts receivable increased by $172.4 million. Cash declined to $412.2 million from $479.7 million at year-end.
• Negative Sentiment: PRVA’s valuation remains demanding, with a reported price-to-earnings ratio near 150. Heavy insider selling cited in recent data may also weigh on sentiment, even though the company’s operating results and outlook improved.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.